FY2025 EPS Estimates for ChromaDex Lifted by HC Wainwright

ChromaDex Co. (NASDAQ:CDXC) – HC Wainwright upped their FY2025 earnings estimates for shares of ChromaDex in a research report issued to clients and investors on Monday, November 4th. HC Wainwright analyst R. Selvaraju now expects that the company will earn $0.21 per share for the year, up from their prior forecast of $0.12. HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for ChromaDex’s current full-year earnings is $0.01 per share.

ChromaDex (NASDAQ:CDXC) last issued its quarterly earnings results on Thursday, October 31st. The company reported $0.02 earnings per share for the quarter. The company had revenue of $25.58 million during the quarter, compared to analyst estimates of $23.70 million. ChromaDex had a net margin of 1.62% and a return on equity of 4.85%. During the same period in the prior year, the business posted ($0.01) EPS.

Separately, Roth Mkm lifted their target price on shares of ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Wednesday.

ChromaDex Stock Up 14.4 %

Shares of NASDAQ:CDXC opened at $6.99 on Wednesday. The company has a market cap of $530.77 million, a P/E ratio of 699.00 and a beta of 1.88. The company’s fifty day moving average is $3.70 and its two-hundred day moving average is $3.28. ChromaDex has a 12-month low of $1.32 and a 12-month high of $7.08.

Insider Transactions at ChromaDex

In other news, Director Kristin Patrick sold 23,000 shares of the company’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $3.57, for a total value of $82,110.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 9.64% of the stock is currently owned by insiders.

Institutional Investors Weigh In On ChromaDex

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Miracle Mile Advisors LLC acquired a new position in shares of ChromaDex in the 2nd quarter valued at $27,000. The Manufacturers Life Insurance Company bought a new position in ChromaDex in the second quarter valued at approximately $31,000. Merriman Wealth Management LLC acquired a new position in shares of ChromaDex in the second quarter valued at approximately $32,000. Lazard Asset Management LLC bought a new stake in shares of ChromaDex during the first quarter worth $43,000. Finally, SG Americas Securities LLC acquired a new stake in shares of ChromaDex during the first quarter worth $54,000. Institutional investors own 15.41% of the company’s stock.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.